BIOTRONIK Announces First Enrollment in CRT-Next Study

BIOTRONIKBIOTRONIK has announced first enrollment in a multicenter study that aims to demonstrate that a two-lead cardiac resynchronization therapy (CRT) system with atrial sensing is at least as effective as a conventional three-lead system. BIOTRONIK's CRT-DX technology provides therapy through two ventricular leads and features a floating dipole for complete atrial diagnostics without an additional lead. The study is sponsored by the Italian patient organization 'Associazione Portatori Dispositivi Impiantabili Cardiaci' (Association of Implantable Cardiac Devices Patients, APDIC).

"We are proud to be a volunteer association that has become a promoter of CRT," said Dr. Armando Luisi, president of APDIC. "Regardless of the outcome of the CRT-Next study, the findings will be useful to improve the quality of life of patients who need CRT devices."

As CRT-D patients are exposed to a higher risk of complication compared to other cardiac implantable electronic device (CIED) patients, managing risk is important. The CRT-DX system offers AV-synchronous CRT pacing without a separate atrial lead for patients not requiring atrial pacing. In reducing system complexity by eliminating the atrial lead, the CRT-DX system is designed to lower the risk of lead-related adverse events.

"This study was initiated to respond to a specific patient need: to benefit the most from the therapies available with the least risk of adverse events," reported Dr. Mauro Biffi, chief investigator of the Policlinico Sant'Orsola Malpighi, Bologna, Italy, and coordinator of the study, after implanting the novel CRT-DX system in the first patient in the CRT-Next study. "Each patient receives everything that is needed for clinical improvement while avoiding lead redundancy which can cause unfavorable problems. In Italy, this is the first clinical study in the field of implantable devices that is promoted by a non-profit association working in the interest of patients. The study reflects the solid cooperation that can be established between healthcare professionals when the objectives are clear and aim at improving care and quality of life."

The CRT-Next study is being conducted in twenty Italian centers. It enrolls 640 patients with optimized therapy for heart failure with an indication for the implantation of a CRT device.

"The technology impact for patients with heart failure and indication for a CRT-DX device can be significantly improved with the CRT-NEXT study," said Dr. Gabriele Zanotto, Head of the Unit of Pacing and Electrophysiology at the Mater Salutis Hospital in Legnago, Italy, who recently enrolled his first patient in the study. "The possibility to demonstrate that we can reduce complications in these patients is the essence of this study. We have full confidence in its scientific impact."

About BIOTRONIK

BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.

Most Popular Now

Artificial Intelligence Detects a New Cl…

Many mutations in DNA that contribute to disease are not in actual genes but instead lie in the 99% of the genome once considered "junk." Even though scientists have recently...

Essen University Medicine and Siemens He…

The Essen University Medicine, Germany's leading hospital company for digitalized medicine, and Siemens Healthineers, a world-leading medical technology company, plan to work together to develop the hospital of the future...

Final Cohort Selected For Pioneering Dig…

Propel@YH has announced the six start-ups to participate in its inaugural digital health accelerator programme, aimed at navigating the complex healthcare landscape and building an NHS-relevant business case. The Leeds-based...

New Kid on the Block: The Doctrina Acade…

The Doctrina Academy is a new service, developed by Doctrina, a video e-learning platform that reaches over 1,000,000 healthcare professionals (HCPs) from around the globe, helping them to switch ...

Efficacy and SilverCloud Health Supports…

A leading mental health service is using the digital mental health platform developed by SilverCloud Health to support a confidential NHS service for GPs in England. London-based Efficacy is offering...

Gloucestershire Hospitals to Deliver EPR…

Gloucestershire Hospitals NHS Foundation Trust is moving to a 'clinical wrap' strategy to deliver an electronic patient record (EPR) and achieve the highest levels of digital maturity within five-years. The...

Mobile Phone App Designed to Boost Physi…

Activity trackers and mobile phone apps are all the rage, but do they really help users increase and maintain physical activity? A new study has found that one mobile phone...

Application Period for an International …

The Master of Science (M.Sc.)in Medical Informatics (MMI) at European Campus Rottal-Inn (ECRI) in Pfarrkirchen - a branch of the Deggendorf University of Applied Sciences (THD - Technische Hochschule Deggendorf)...

NHS Prescribing is Back in the Spotlight…

Opinion Article by Dr Simon Hendricks, Product Innovation Manager and Clinical Strategy Lead, FDB (First Databank) Political will for better and safer prescribing in the NHS has fast gained momentum in...

Sectra to Provide Large Centralized Regi…

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a five-year contract with North Tees and Hartlepool NHS Foundation Trust for the delivery of a regional...

IMI to Boost Patient Involvement in its …

The Innovative Medicines Initiative (IMI) is creating a 'pool' of patient experts to strengthen the role and voice of patients in IMI activities at both strategic and operational levels. IMI...